Pomerantz says Aevex investors face Oct. 20 lead-plaintiff deadline
Pomerantz LLP said a class action has been filed against AEVEX Corp. and that investors who bought the company’s securities during the class period may ask a court to appoint a lead plaintiff by Oct. 20, 2026.
Pomerantz LLP said a class action has been filed against AEVEX Corp. and that investors who bought the company’s securities during the class period may ask a court to appoint a lead plaintiff by Oct. 20, 2026.
Pomerantz LLP said in a Sept. 3, 2026, notice that a class action has been filed against AEVEX Corp. (NYSE: AVEX) over alleged securities fraud or other unlawful business practices involving the company and certain officers and directors.
The notice said investors who bought or otherwise acquired Aevex securities during the class period can seek appointment as lead plaintiff. Pomerantz said the filing deadline is Oct. 20, 2026.
The notice said Aevex held its initial public offering on or around April 17, 2026, selling 16 million shares of Class A common stock at $20.00 per share. It also said the complaint alleges that certain directors, officers and IPO underwriters made materially false and misleading statements and omissions about a pre-arranged plan to waive the 180-day lock-up period.
According to the notice, the market learned the alleged truth in June 2026, and Aevex’s stock price fell sharply, damaging investors. The notice did not provide further details on the stock move.
Pomerantz identified Danielle Peyton as the contact for investor inquiries and said email inquiries should include a mailing address, telephone number and number of shares purchased. The notice listed [email protected], 646-581-9980 and 888-4-POMLAW ext. 7980.
Investors who purchased or otherwise acquired Aevex securities during the class period have until Oct. 20, 2026, to ask the court to appoint them as lead plaintiff.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
View the Web StoryA visual, tap-through version of this reportThis is the AMP version of the article. Read the full article on Atlas Watchline.